HomeStartups SciSparc lifecycle

Claimed by owner Last Update Jun 4, 2026 Suggest Edits Claim Profile

Claimed by owner

SciSparc

Former names: Therapix Biosciences, Nasvax

Cannabinoid Pharmaceuticals for Treatment of Central Nervous System Disorders

PUBLIC on NASDAQ on Mar 2017

SciSparc

SciSparc Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd.

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Neurothera Labs Inc. Announces Definitive Agreement to Acquire Majority Stake in Cliniquantum Ltd.

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc announces 1-for-9 reverse share split

#PIPE/PO

SciSparc Announces 1-for-9 Reverse Share Split

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance Such as MRSA

#Product Stage

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

#Product Stage

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

#Acquisition #Partners

BC-Most Active Stocks

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

#Acquisition #Partners

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

#Public Trading

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

#Product Stage

Neurothera Labs Granted Patent by Israeli Patent Office for Its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

#Product Stage

IM Cannabis Appoints Asi Levi as Chief Financial Officer

#Management Changes

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

#Acquisition

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

#Acquisition

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

#Acquisition #Partners

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

#Acquisition #Partners

BC-Most Active Stocks

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

#Product Stage #Partners

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

#Product Stage #Partners

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

#Product Stage #Partners

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

#Acquired-by #Acquisition

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

#Acquisition

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

#Product Stage

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

#Acquired-by

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

#Acquisition

SciSparc And AutoMax Call Off Merger

#Acquired-by #Partners

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

#Acquired-by

SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

#Acquired-by

Top Midday Gainers

N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

#Acquisition #Investment

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

#Product Stage

Wall Street Set to Open Little Changed Wednesday as Investors Anticipate Fed Rate Cut

SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc

#Acquisition

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

#Acquisition

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

#Product Stage #Partners

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

#Product Stage #Partners

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

#Acquired-by

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

#Product Stage #Partners

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

#Product Stage #Partners

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

#Product Stage

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

#Product Stage #Partners

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

#Product Stage #Partners

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

#Product Stage #Partners

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

#Product Stage #Partners

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

#Product Stage #Partners

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

#Acquired-by

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

#Acquired-by #Acquisition

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

#Acquisition #Investment

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

#Product Stage #Management Changes

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

#Product Stage #Partners

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

#Partners #Acquired-by

SciSparc says MitoCareX expands research to pancreatic cancer

#Product Stage

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

#Product Stage #Partners

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

#Partners #FDA approved/pending approval #Product Stage

Sector Update: Health Care Stocks Edge Higher Premarket Monday

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

#Product Stage #Partners

IMCA renews SciSparc’s autism spectrum disorder therapy trial approval

#Partners

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

SciSparc: AutoMax announces $13M first delivery of JAC vehicles

#Acquired-by #Partners

SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment

#Acquired-by #Partners

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

#Partners #Acquisition

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

#Acquired-by

Jeffs’ Brands announces trademark registration approval for Wellution

#Partners

SciSparc receives FDA approval for trial for Tourette syndrome therapy

#Customers

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

#Customers

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

#Investment

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

#Customers

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

#Customers

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

#Partners

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer

#Investment #Partners #Acquisition

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

#Partners

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

#Partners

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

#Partners

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

#Partners

SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial

#Customers

SciSparc secures final approval in Israel to start Tourette’s Syndrome trial

#Customers

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

#Investment #Expand

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

#Management Changes #Partners

SciSparc and Polyrizon sign global agreement for pain therapy

#Partners #Investment

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

#Customers #Expand

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

#Partners #Investment

SciSparc Updates Regarding the Status of the AutoMax Merger

#Acquired-by

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

#Partners #Investment

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

#Investment, Partners

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

#Partners #Investment

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

#Public Trading

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

#Partners #Investment

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

#Acquisition #Investment

SciSparc Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio

#Management Changes

SciSparc Secures Strategic Advantage with Grant of European Patent

#Customers

SciSparc to Acquire AutoMax

#Acquisition

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

#Partners #Investment

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

#Partners

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

#Investment

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

#Customers

SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure

#Partners, Investment

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

#Customers

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

#Investment

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

#Customers

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

#Customers

EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds

#Partners

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

#Partners

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

#Partners #Expand

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

#Partners

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

#Partners #Expand

SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

#Customers #Expand

SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement

#Investment

SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million

#Investment #Acquisition

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

#Partners #Investment

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

#Partners

SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform

#Investment #Partners

SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel

#Acquisition

Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial

#Partners #Expand

SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

#Partners

SciSparc Adopts Limited Duration Shareholder Rights Plan

#Management Changes

New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder

#Customers #Partners

SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

#Acquired-by #Management Changes

SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation

#Investment #Customers

SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

#Customers #Investment

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

#Customers

SciSparc Granted Patent for its Core Technology From the Australian Patent Office

#Customers #Investment

Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC)

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Ltd. Announces Closing of $5.026 Million Private Placement

#Investment

SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement

#Investment

SciSparc Granted European Patent for its Core Technology

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder

#Customers #Partners

SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

#Public Trading

SciSparc Announces 1-for-26 Reverse Share Split

#Public Trading

SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities

#Partners #Investment

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

#Public Trading

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

#Investment #Expand

Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)

#Public Trading

SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering

#Investment #Public Trading

SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering

#Investment #Public Trading

SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million

#Public Trading #Investment

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

#Partners #Investment

EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio

#Investment #Partners

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

#Partners #Expand

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

#Customers #Expand

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

#Customers

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

#Customers

EXCLUSIVE: SciSparc's Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US

#Customers #Investment

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

#Partners

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

#Partners

SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals

#Partners #Customers

Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada

#Partners #Expand

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

#Customers

SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

#Management Changes

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program

SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation

#Investment

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

#Partners #Expand

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder

#Partners #Expand

Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million

SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System

#Investment

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

#Partners

SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

#Customers

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

#Partners

SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand

#Partners

SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer's Disease Patients with Agitation

#Customers

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

#Partners #Investment

SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

#Partners #Expand

SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial

#Partners #Customers

SciSparc Presents New Leadership Lineup

#Management Changes

SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110

#Partners

https://www.marketwatch.com/story/scisparc-shares-rise-9-after-exploring-psychedelics-as-possible-way-to-expand-portfolio-271641917023#:~:text=Dow%20Jones%20Newswires-,SciSparc%20Shares%20Rise%209%25%20After%20Exploring%20Psychedelics,Possible%20Way%20to%20Expand%20Portfolio&text=SciSparc%20Ltd.%20shares%20were%20up,for%20its%20intellectual%20property%20portfolio.

SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease

#Customers

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

#Investment

SciSparc Provides Updates Upon Conclusion of 2021

#Investment #Partners #Expand

SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today

#Public Trading

SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market

#Public Trading

https://www.prnewswire.com/il/news-releases/scisparc-announces-the-publication-of-a-manuscript-describing-the-tourette-syndrome-study-conducted-at-yale-university-301402161.html

#Customers

SciSparc Announces Completion of Corporate Rebranding and Launch of New Website

#Customers #Investment

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

#Customers

SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome

#Partners #Expand

SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitation

#Customers

SciSparc to Support 31st Annual ICRS Symposium on Cannabinoids Special Event

#Customers #Partners

SciSparc to Commence a Pre-Clinical Study Using its SCI-210 Cannabidiol Based Treatment for Epilepsy

#Partners

SciSparc Awarded Three Patents For Its Novel Compounds and Methods

#Investment

SciSparc Ltd. Announces $8.15 Million Private Placement

#Investment

SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment

#Partners

Therapix Biosciences Announces Name Change to SciSparc Ltd.

#Management Changes

Therapix Biosciences Announces Pricing of $4.2 Million Offering

#Investment

Therapix Biosciences Announces Replacement of its Board of Directors BioSpace

#Management Changes

Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court

#Public Trading

Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli Court

#Public Trading #Investment

Therapix Biosciences Raises $2.6 Million in Private Placement

#Investment

Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication

#Partners #Investment

Therapix Biosciences Announces Appointment of New CEO

#Management Changes

Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements

#Public Trading

Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering

#Investment

Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

#Customers #Expand

Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal

#Public Trading

The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

#Partners #Acquisition

Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.

#Acquisition #Partners #Investment

Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

#Acquisition

Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

#Customers

Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement

#Public Trading #Acquisition

Therapix Biosciences announces Canadian Product License Issuance for CannAmide

#Partners #Acquisition

Cannabis Companies Therapix and Destiny to Merge

#Acquisition

Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program BioSpace

#Customers

Therapix Biosciences: developing cannabinoid products of the future

Cannabis Company Therapix Biosciences to Raise $2.25 Million in Direct Offering

#Investment

Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor

#Management Changes

FSD Pharma's Acquisition of Therapix Hits a Snag

#Acquisition

Canada's FSD Pharma to Acquire Israeli Therapix Biosciences for $48 Million in Stock

#Acquisition

http://therapix.investorroom.com/2018-07-17-Therapix-Biosciences-Announces-Positive-Data-From-Recent-Pre-clinical-Studies-for-its-Drug-Candidate-THX-160-for-Treatment-of-Pain

http://therapix.investorroom.com/2018-06-11-Therapix-Biosciences-Sponsors-the-2018-Annual-Meeting-of-the-European-Society-for-the-Study-of-Tourette-Syndrome

http://therapix.investorroom.com/2018-06-05-Therapix-Biosciences-Announces-Enrollment-of-the-First-Patient-for-Clinical-Trial-at-Assuta-Medical-Center-for-Treating-Obstructive-Sleep-Apnea-Using-Cannabinoid-based-Drug

Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange

#Public Trading

http://therapix.investorroom.com/2018-04-09-Therapix-Biosciences-Announces-Topline-Results-of-Phase-IIa-Study-at-Yale-University-for-Tourette-Syndrome-Program

http://therapix.investorroom.com/2018-03-20-Therapix-Biosciences-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-for-Phase-IIa-Clinical-Trial-of-THX-110-in-the-Treatment-of-Chronic-Low-Back-Pain

http://therapix.investorroom.com/2018-02-07-Therapix-Biosciences-Completes-Pre-IND-Communication-With-FDA-on-THX-110-for-Tourette-Syndrome-Clinical-Development-to-Proceed-as-Projected

http://therapix.investorroom.com/2018-01-09-Therapix-Biosciences-Announces-Expansion-into-Precision-Medicine-Through-New-Fully-Owned-Subsidiary-and-Provides-Corporate-Update-Today-at-the-Biotech-Showcase-TM-2018

Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center

#Partners #Customers

Therapix Biosciences Announces CEO Change

#Management Changes

Israeli medical cannabis co Therapix lists on Nasdaq

#Investment #Public Trading

Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing

#Public Trading

Therapix Biosciences Signed a Binding MOU With a Swiss Pharmaceutical Development Company, to Receive a License to Use a Formulation for Ultralow-Dosage Administration

#Partners

Therapix Biosciences Filed an Application with the FDA to Approve an "Orphan" Designation for the Drug Developed Based on the Entourage Technology for Treating Tourette's Syndrome

#Investment

Therapix Biosciences ADRs Begin Trading on the OTCQB(R)

#Public Trading

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

8/2004

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

SciSparc Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

SciSparc Financials

Total funding Undisclosed

Market cap Undisclosed

Last funding Undisclosed

Funding stage undefined

Total rounds undefined

Investors undefined

Cumulative Funding Raised Over Time ($)

Public Offerings & Exits

Public Offering

$1.3M

Aug 2023

Stock Exchange

NASDAQ

Valuation Undisclosed

$1.3M

Public Offering

Undisclosed

Dec 2021

Stock Exchange

NASDAQ

Valuation Undisclosed

Undisclosed

Stock Exchange

OTC

Public Offering

$4.2M

Nov 2020

Stock Exchange

OTC

Valuation Undisclosed

$4.2M

Public Offering

Undisclosed

Jul 2020

Stock Exchange

OTC

Valuation Undisclosed

Undisclosed

Stock Exchange

TASE

Public Offering

$12M

Mar 2017

Stock Exchange

NASDAQ

Valuation Undisclosed

$12M

Initial Public Offering EXIT

$10.4M

Dec 2005

Stock Exchange

TASE

Valuation Undisclosed

$10.4M

Private Equity Funding

PIPE

$9.18M

Jan 2026

$9.18M

PIPE

$5.03M

Oct 2023

1 Investors

$5.03M

PIPE

$10M

Jun 2022

1 Investors

$10M

PIPE

$8.15M

Mar 2021

1 Investors

$8.15M

PIPE

$1.25M

Dec 2019

1 Investors

$1.25M

PIPE

$2.25M

Apr 2019

1 Investors

$2.25M

Mergers and Acquisitions

M&A

Undisclosed

Oct 2025

Type Acquisition

Acquired

Neurothera Labs

Undisclosed

M&A

Undisclosed

Oct 2014

Type Acquisition

Acquired

Dekel Pharmaceuticals

Undisclosed

M&A

$2.3M

Aug 2014

Type Acquisition

Acquired

Lara Pharm

$2.3M

SciSparc Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

PIPE

$9.18M

Jan 2026

$9.18M

Type Acquisition

Acquired

Neurothera Labs

Undisclosed

PIPE

$5.03M

Oct 2023

1 Investors

$5.03M

Stock Exchange

NASDAQ

Valuation Undisclosed

$1.3M

PIPE

$10M

Jun 2022

1 Investors

$10M

Stock Exchange

NASDAQ

Valuation Undisclosed

Undisclosed

Stock Exchange

OTC

PIPE

$8.15M

Mar 2021

1 Investors

$8.15M

Stock Exchange

OTC

Valuation Undisclosed

$4.2M

Stock Exchange

OTC

Valuation Undisclosed

Undisclosed

PIPE

$1.25M

Dec 2019

1 Investors

$1.25M

PIPE

$2.25M

Apr 2019

1 Investors

$2.25M

Stock Exchange

TASE

Stock Exchange

NASDAQ

Valuation Undisclosed

$12M

Type Acquisition

Acquired

Dekel Pharmaceuticals

Undisclosed

Type Acquisition

Acquired

Lara Pharm

$2.3M

Stock Exchange

TASE

Valuation Undisclosed

$10.4M

News Over Time

News Articles